Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19325318 | 0.81 | — | — | |
| SCHEMBL24242135 | 0.76 | TSHR (0.42) | TSHRALDH1A1 | |
| SCHEMBL891740 | 0.73 | — | — | |
| SCHEMBL13786356 | 0.73 | — | — | |
| SCHEMBL9493736 | 0.73 | TSHR (0.44) | TSHRALDH1A1 | |
| SCHEMBL18973793 | 0.70 | — | — | |
| SCHEMBL8723924 | 0.69 | TSHR (0.54) | TSHRALDH1A1HPGD | |
| SCHEMBL28396873 | 0.69 | TSHR (0.53) | TSHRALDH1A1 | |
| Ethylenediamine SCHEMBL7702384 | 0.68 | TSHR (0.43) | TSHRALDH1A1 | |
| SCHEMBL891686 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170252347-A1 | DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases | MITOCHON PHARMACEUTICALS, INC. | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170252347-A1 | DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases | SMN1; SMN2, MYLK2, WFS1 | TSHR 3498/4885ALDH1A1 2044/4885HPGD 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.